BOC International: Maintaining Kingsley Biotech's (01548) “Buy” Rating Target Price of HK$27.75
Kingsley Biotech (01548) guides strong annual revenue growth of 15%-20% and 20%-30% (@CER, i.e. Comparative Effects Study).
Kingsley Biotechnology (01548.HK): The European Commission approved CARVYKTI for second-line treatment of patients with recurrent refractory multiple myeloma
Gelonghui, April 23 | Kingsley Biotech (01548.HK) issued an announcement. On April 22, 2024, Legend Biotech issued a press release announcing that the European Commission (EC) approved CARVYKTI (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with recurrent and refractory multiple myeloma. These patients have received at least one treatment in the past, including proteasome inhibitors (PI) and immunomodulators (IMID). The patients showed disease progression during the last treatment , and lenalidomide is difficult to treat
金斯瑞生物科技:2023年度報告
Kingsley Biotechnology (1548.HK): Global layout, business blossoming, innovative drug business entering a commercialization period
Under the intertwined influence of the risk factors of globalization, how can enterprises persevere and continue to move forward in the midst of turbulence has become a common problem in the industry. However, Kingsley seemed to have given his own unique answer with an excellent questionnaire.
Trending Industry Today: GENSCRIPT BIO Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
April 19th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending lower today with 9 constituents down and GENSCRIPT BIO leading Losses.$GENS
Changes in Hong Kong stocks | CRO concept stocks continue to decline, the Federal Reserve does not rule out possible interest rate hikes, domestic innovative drugs are still in an adjustment cycle
The Zhitong Finance App learned that CRO concept stocks continued to decline. As of press release, Tiger Pharmaceuticals (03347) fell 7.94% to HK$28.4; Kingsley Biotech (01548) fell 5.93% to HK$10.78; Kanglong Chemical (03759) fell 4.83% to HK$8.47; and Pharmaceuticals (02359) fell 4.5% to HK$32.9. According to the news, overnight, Federal Reserve officials made hawkish remarks. New York Federal Reserve Chairman Williams said that if the data reminds us that we need to raise interest rates to achieve our goals, then we will obviously do it. Furthermore, Asia
Kingsley Biotech: CARVYKTI's net trade sales in the first quarter were about US$157 million
Kingsley Biotech (01548) issued an announcement. On April 16, 2024, Legend Biotechnology Co., Ltd. (Legend Biotech) announced that according to Legend Biotech and Janssen Biotech, Inc. (Janssen) signed a cooperation and licensing agreement on December 21, 2017
Changes in Hong Kong stocks | Kingsley Biotech (01548) fell more than 5%, and the company's stock price hit a new low in recent years. CDMO short-term demand growth and profitability were under pressure
Kingsley Biotech (01548) fell by more than 5%, down 5.59% at press time, to HK$11.48, with a turnover of HK$104 million.
Changes in Hong Kong stocks | Kingsley Biotech (01548) is now up nearly 5% legendary biotech CARVYKTI approved by FDA for second-line treatment of multiple myeloma
The Zhitong Finance App learned that Kingsley Biotech (01548) is now up nearly 5%. As of press release, it has risen 4.75% to HK$13.22, with a turnover of HK$840.661 million. According to the news, Legendary Biotech announced on April 5 that the US Food and Drug Administration (FDA) has approved CARVYKTI (Sidakiolenol) to treat patients with recurrent or refractory multiple myeloma (RRMM). These patients have received at least first-line treatment (including proteasome inhibitors and immunomodulators) and are resistant to lenalidomide. Guolian Securities pointed out that considering 2023 CARVYKTI
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval
Genscript Biotech (HKG:1548) said its non-wholly owned subsidiary Legend Biotech received US Food and Drug Adminstration approval for its drug CARVYKTI, which treats patients with refractory multiple
Zhitong Hong Kong stocks have known for a long time | Ministry of Housing and Construction promotes construction and municipal infrastructure equipment updates and issues imported online game version numbers in April
On April 8, the State Press and Publication Administration released approval information for online games imported in April. A total of 14 games were approved, including “Mega Man 11” by Tencent and “Diversive Million King Arthur: Ring” by Perfect World.
GLONGHUI ANNOUNCEMENT SELECTION (HK Stocks) | China Free Credit (01880.HK) Performance Report: Net profit of RMB2,308 billion for the first quarter increased 0.33% year-on-year
[Today's Focus] China Credit Service (01880.HK) Performance Report: Net profit for the first quarter was 2.308 billion yuan, up 0.33% year-on-year, and China Credit (01880.HK) released a quick performance report for the first quarter of 2024. During the reporting period, with the further recovery of the entry/exit duty-free business, the share of the company's offline business continued to pick up, and the product sales structure continued to be optimized. In the first quarter of 2024, the company achieved operating income of RMB 18.807 billion, a year-on-year decrease of 9.45%; net profit attributable to shareholders of listed companies was RMB 2.308 billion, an increase of 0.33% over the previous year.
Hong Kong Stock Announcement Nuggets | China exempts net profit of 2,308 billion yuan in the first quarter, Tencent and Meituan continue to make major buybacks
Net profit attributable to mother for the first quarter of China Zhongfu (01880) was 2.308 billion yuan, up 0.33% year-on-year
Kingsley Biotechnology (01548.HK): Legendary Biotech announced that the US FDA approved CARVYKTI for second-line treatment of patients with recurrent or refractory multiple myeloma
Glonghui, April 8, 丨 Kingsley Biotechnology (01548.HK) announced that Legend Biotechnology Co., Ltd. (“Legend Biotech”, a non-wholly-owned subsidiary of the company and its shares are listed on the US NASDAQ Global Select Market in the form of American Depositary Shares) has submitted Form 6-K to the US Securities Regulatory Commission on April 5, 2024, and announced that the US Food and Drug Administration (“US FDA”) has approved CARVYKTI (Sidakiolenthel, cilta-cel) for the treatment of patients with recurrent or refractory multiple myeloma Have received at least first-line treatment (package
Kingsley Biotech issues 1392 thousand shares under the adopted restricted share award scheme
Kingsley Biotech (01548) issued an announcement to issue and allocate 139,200 shares on April 2, 2024 in accordance with the restricted share award scheme adopted on August 23, 2021.
Kingsley Biotech (01548) issues 1392 thousand shares under the adopted restricted share award scheme
Kingsley Biotechnology (01548) issued an announcement on April 2, 2024, according to August 23, 2021...
Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Kingsley Biotech (01548) issues 447,900 new shares under the Restricted Share Award Program
Kingsley Biotechnology (01548) issued an announcement on March 25, 2024, based on August 2, 2021...
Medication heats up strongly! Pharmaceutical stocks are rebounding, and the US “Biosafety Act” suddenly becomes a variable?
Also boosted by these factors!
Kingsley Biotech (01548.HK): Legendary Biotech Releases First ESG Report
Gelonghui March 19 | Kingsley Biotechnology (01548.HK) announced that Legend Biotechnology Co., Ltd. (a non-wholly-owned subsidiary of the company) released its first Environmental, Social and Governance (ESG) report on March 19, 2024. The ESG report provides an overview of Legend Biotech's ESG plans and reports that meet the Sustainable Accounting Standards Committee's biotechnology and pharmaceutical industry standards, Legend Biotech's ESG data collection and disclosure roadmap, and future growth areas of its ESG path. The ESG report highlights Legendary Biotech's commitment to patients, employees, and communities, marking Legendary Biotech at E
No Data